Therapeutics News and Research

RSS

Importance of the phosphatidylinositol 3 kinase (PI3K) pathway to breast cancer development

Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center.

13 Dec 2004

Zarnestra, a farnesyl transferase inhibitor, can help treat high-risk myelodysplastic syndrome patients

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

7 Dec 2004

Adenosine Therapeutics awarded grant to develop drug eluting stents to prevent restenosis

Adenosine Therapeutics announced today the award of a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health.

6 Dec 2004

Scientist develops way to deliver promising genetic tool into living cells

By exploiting an HIV protein that readily traverses cell membranes, Carnegie Mellon University scientists have developed a new way to introduce a gene-like molecule called a peptide nucleic acid (PNA) directly into live mammalian cells, including human embryonic stem (ES) cells.

6 Dec 2004

Alliance to develop and commercialize fully-human anti-anthrax antibody

MDX-1303 was developed by Medarex using its UltiMAb Human Antibody Development System, and this antibody is currently in preclinical development by Medarex for use against human anthrax infection.

6 Dec 2004

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

The hopes of many that ALS (commonly referred to as Lou Gehrig's disease) will one day be a disease of the past, studied in medical textbooks, conquered by the dedication of those who have worked tirelessly to eradicate it might be realized in our lifetime.

6 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Oral targeted therapy shows benefit in treating high-risk myelodysplastic syndrome

4 Dec 2004

Fossil record of the human immune system reveals antibodies that block cancer metastasis

A team of researchers at The Scripps Research Institute has reconstructed the "fossil record" of the immune systems of a group of human cancer patients to investigate if they had ever produced antibodies against their disease.

4 Dec 2004

New research may lead to treatments for atherosclerosis

Scientists are one step closer to deciphering the molecular signaling process controlling innate immunity with the discovery that a molecule called IRAK1 regulates the expression of the anti-inflammatory cytokine IL-10. Because atherosclerosis patients often have elevated IL-10 levels, IRAK1 may be a viable target for developing therapeutics for atherosclerosis.

29 Nov 2004

FDA approves Remodulin for the treatment of pulmonary arterial hypertension

United Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has issued an approval letter for the intravenous use of Remodulin based on data establishing its bioequivalence with the previously approved subcutaneous administration of Remodulin.

24 Nov 2004

Discovery of a new cancer gene, which, when damaged, may promote prostate cancer

Together with an international research team, researchers from VTT Technical Research Centre of Finland have developed an effective method for the screening and identification of genes that under normal conditions suppress cancer growth.

24 Nov 2004

Survey shows need for conservative, drug-free options

A new survey showing that nearly half of all Americans are concerned about the safety of the medical care they receive should send a strong signal to the health and insurance industries that safer non-drug, non-surgical treatments should be considered whenever possible, according to the American Chiropractic Association (ACA).

20 Nov 2004

Scientists have determined the crystal structure of a protein kinase C (PKC) isozyme

This structure should prove extremely useful in the rational design of small molecule inhibitors of PKCÈ, which has been implicated in T-cell mediated disease processes including inflammation and autoimmunity.

19 Nov 2004

Overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) reduces tumor growth

Scientists have found that overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) blocks the formation of new blood vessels and thus reduces tumor growth. Therapeutics based on this finding may potentially lead to new cancer treatments.

19 Nov 2004

Capsules may be effective in treating bipolar disorder

University of North Carolina at Chapel Hill researchers have announced study results finding that a formulation of three-beaded extended-release carbamazepine capsules (ERC-CBZ) was effective, safe and tolerable in the treatment of bipolar I disorder

19 Nov 2004

Family experience guides Alzheimer’s research

After watching his father struggle with and ultimately succumb to Alzheimer’s disease, ASU professor Michael Sierks shifted his research focus from starch hydrolyzing to neurodegenerative diseases.

18 Nov 2004

New findings have implications for chronic use of COX-2 Inhibitors in pre-menopausal women

Heart disease is less pronounced in women than in men as humans age, but this difference narrows after menopause. Some studies have shown that estrogen slows heart disease in mouse models, but the mechanism is largely unknown.

18 Nov 2004

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Directed Against R1 and R2 Components of Ribonucleotide Reductase."

10 Nov 2004

Nanogen announces clinical diagnostic to simultaneously detect multiple respiratory viruses

Nanogen announced today that it is developing new analyte specific reagents (ASRs) for clinical reference laboratories to develop and validate a single test to detect six of the most common respiratory viruses.

10 Nov 2004

Therapeutics News and Research

Importance of the phosphatidylinositol 3 kinase (PI3K) pathway to breast cancer development

Zarnestra, a farnesyl transferase inhibitor, can help treat high-risk myelodysplastic syndrome patients

Adenosine Therapeutics awarded grant to develop drug eluting stents to prevent restenosis

Scientist develops way to deliver promising genetic tool into living cells

Alliance to develop and commercialize fully-human anti-anthrax antibody

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Oral targeted therapy shows benefit in treating high-risk myelodysplastic syndrome

Fossil record of the human immune system reveals antibodies that block cancer metastasis

New research may lead to treatments for atherosclerosis

FDA approves Remodulin for the treatment of pulmonary arterial hypertension

Discovery of a new cancer gene, which, when damaged, may promote prostate cancer

Survey shows need for conservative, drug-free options

Scientists have determined the crystal structure of a protein kinase C (PKC) isozyme

Overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) reduces tumor growth

Capsules may be effective in treating bipolar disorder

Family experience guides Alzheimer’s research

New findings have implications for chronic use of COX-2 Inhibitors in pre-menopausal women

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Nanogen announces clinical diagnostic to simultaneously detect multiple respiratory viruses

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News